The two most common forms of HGGs are glioblastoma (GBM) and anaplastic astrocytoma
2006) documented significantly lower levels of serum IL-12 and higher levels of IL-10 among newly diagnosed patients with anaplastic astrocytoma
Interestingly, of the 15 patients with anaplastic astrocytoma
, all who had normal serum AHSG (n = 5) survived >2 years, whereas those with low serum AHSG (n = 10) had a median survival of <10 months.
A snapshot of the global therapeutic scenario for Anaplastic Astrocytoma
This product is the generic equivalent to TemodarA (temozolomide), indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment and refractory anaplastic astrocytoma
patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine.
2) Anaplastic gliomas are characterized by loss of 9p and homozygous deletion of the CDKN2A/B gene (p16/p15), and the progression of an anaplastic astrocytoma
to a secondary GBM is frequently associated with 10q loss.
Further analysis of their data showed that glioblastoma and anaplastic astrocytoma
patients carrying the mutations survived longer than those who did not, and note that additional studies of how the gene works may reveal why this occurs.
TEMODAL is currently marketed in Canada for the treatment of recurrent or progressive GBM or anaplastic astrocytoma
(AA), another form of brain tumor.
She then presented with increased seizure activity, and a biopsy confirmed a more aggressive tumor--an anaplastic astrocytoma
GlobalData's clinical trial report, Anaplastic Astrocytoma
Global Clinical Trials Review, H1, 2012" provides data on the Anaplastic Astrocytoma
clinical trial scenario.
The company's lead investigational combination product, Toca 511 & Toca FC, is advancing into a pivotal Phase 2/3 study in 2015 for patients with recurrent glioblastoma or anaplastic astrocytoma
For example, it uses mitotic activity to distinguish anaplastic astrocytoma
(AA), WHO grade III, from its low-grade counterpart, diffuse astrocytoma, WHO grade II.